Latest market price
5.91
+0.10+1.72%
Earnings
Up 1.7% — Reported earnings — EPS missed by 64%, revenue missed by 13%.
High confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.68 | Insider Own | — | Shs Outstand | 136.34M | Perf Week | -0.34% |
| Market Cap | 805.79M | Forward P/E | — | EPS next Y | -0.03 | Insider Trans | 0.06% | Shs Float | 86.36M | Perf Month | 5.54% |
| Enterprise Value | 2.77B | PEG | — | EPS next Q | -0.05 | Short Float | 11.85% | Perf Quarter | -11.92% | ||
| Income | -228.00M | P/S | 0.27 | EPS this Y | -129.36% | Short Ratio | 3.41 | Perf Half Y | -54.68% | ||
| Sales | 3.01B | P/B | 0.58 | EPS next Y | — | ROA | -5.26% | Short Interest | 10.24M | Perf YTD | -40.66% |
| Book/sh | 10.17 | P/C | 18.74 | EPS next 5Y | — | ROE | -15.16% | 52W High | 13.43 -55.99% | Perf Year | -33.97% |
| Cash/sh | 0.32 | P/FCF | 8.22 | EPS past 3/5Y | — | ROIC | -0.24% | 52W Low | 5.21 13.44% | Perf 3Y | -19.37% |
| Dividend Est. | — | EV/EBITDA | 9.53 | Sales past 3/5Y | 2.98% 25.17% | Gross Margin | 10.37% | Volatility | 4.70% 4.28% | Perf 5Y | -76.40% |
| Dividend TTM | — | EV/Sales | 0.92 | EPS Y/Y TTM | -411.11% | Oper. Margin | -0.31% | ATR (14) | 0.26 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 0.98 | Sales Y/Y TTM | 14.54% | Profit Margin | -7.58% | RSI (14) | 47.47 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.12 | EPS Q/Q | — | SMA20 | -2.02% | Beta | 1.30 | Target Price | 9.83 |
| Payout | 0.00% | Debt/Eq | 1.45 | Sales Q/Q | 25.00% | SMA50 | 0.39% | Rel Volume | 1.04 | Prev Close | 5.81 |
| Employees | 10,900 | LT Debt/Eq | 1.44 | Earnings | Nov 03 | SMA200 | -35.53% | Avg Volume | 2.92M | Price | 5.91 |
| IPO Date | May 31, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -64.45% -12.57% | Net Debt/EBITDA | 6.76 | Volume | 3,040,257 | Change | 1.72% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-26 | Reiterated | Robert W. Baird | $10 → $9.00 | |
| Aug-06-26 | Reiterated | RBC Capital | Outperform | $15 → $8.00 |
| Aug-06-26 | Reiterated | UBS | Buy | $13 → $10 |
| Aug-05-26 | Reiterated | Robert W. Baird | $15 → $10 | |
| Aug-05-26 | Reiterated | Canaccord Genuity | Buy | $16 → $10 |
| Aug-05-26 | Reiterated | Truist Securities | Buy | $12 → $9.00 |
| Jul-21-26 | Upgrade | Jefferies | Hold → Buy | $11 → $13 |
| Jul-06-26 | Reiterated | Robert W. Baird | $18 → $15 | |
| May-11-26 | Reiterated | RBC Capital | Outperform | $13 → $15 |
| May-06-26 | Reiterated | Robert W. Baird | $17 → $18 |
Latest News· Times ET
Nov-02-26
Oct-21-26
08:00AM
Oct-14-26
Sep-22-26
Sep-21-26
Sep-17-26
Sep-11-26
Sep-09-26
Sep-08-26
Sep-01-26
Sep-01-2602:58PM
Aug-17-26
Aug-17-2609:00AM
Aug-14-26
Aug-14-2607:44PM
Aug-12-26
Aug-12-2610:09AM
Aug-11-26
Aug-11-2610:05AM
Company
AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,009 | 3,245 | 3,261 | 3,200 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,696 | 2,676 | 2,580 | 2,518 | — | — | — | — | — | |
| Gross Profit | 311 | 569 | 681 | 682 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 385 | 382 | 359 | 190 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | -63 | 0 | 58 | 1,090 | — | — | — | — | — | |
| Operating Income | -10 | 186 | 264 | -598 | — | — | — | — | — | |
| Interest Expense | 101 | 106 | 127 | 130 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -135 | -96 | -1 | 5 | — | — | — | — | — | |
| Net Income Before Taxes | -247 | -15 | 136 | -724 | — | — | — | — | — | |
| Income Taxes | -11 | 51 | 41 | -49 | — | — | — | — | — | |
| Consolidated Net Income | -228 | -71 | 90 | -679 | — | — | — | — | — | |
| Net Income From Continuing Operations | -235 | -66 | 95 | -675 | — | — | — | — | — | |
| Net Income | -228 | -71 | 90 | -679 | — | — | — | — | — | |
| EPS (Recurring) | -1.68 | -0.52 | 0.62 | -5.32 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.68 | -0.52 | 0.62 | -5.32 | — | — | — | — | — | |
| EPS (Diluted) | -1.68 | -0.52 | 0.61 | -5.31 | — | — | — | — | — | |
| EBITDA | 291 | 473 | 628 | -171 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 15.61 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.27 | 0.41 | 0.39 | 0.31 | — | — | — | — | — | |
| Gross Margin | 10.34 | 17.53 | 20.88 | 21.31 | — | — | — | — | — | |
| Operating Margin | -0.33 | 5.73 | 8.10 | -18.69 | — | — | — | — | — | |
| Net Margin | -7.58 | -2.19 | 2.76 | -21.22 | — | — | — | — | — | |
| Shares Outstanding | 136 | 135 | 134 | 134 | — | — | — | — | — | |
| Market Capitalization | 804 | 1,345 | 1,276 | 977 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| WOLF DALE B | Director | Aug 06 '26 | Buy | 6.33 | 40,000 | 253,400 | 143,234 | Aug 14 |
| WOLF DALE B | Director | Aug 07 '26 | Buy | 5.86 | 20,000 | 117,200 | 34,000 | Aug 10 |
| SAMET KENNETH A | Director | Aug 06 '26 | Buy | 6.38 | 23,500 | 149,930 | 48,569 | Aug 10 |
| Schuster III Russell E. | Chief Commercial Officer | Jul 01 '26 | Sale | 10.44 | 11,275 | 117,711 | 125,263 | Jul 06 |
| Schuster III Russell E. | Chief Commercial Officer | Jun 01 '26 | Sale | 10.06 | 11,275 | 113,427 | 136,538 | Jun 03 |
| OEP VII GP, L.L.C. | 10% Owner | Mar 20 '26 | Buy | 9.91 | 447,100 | 4,431,700 | 16,312,698 | Mar 30 |
| OEP VII GP, L.L.C. | 10% Owner | Mar 19 '26 | Buy | 9.94 | 727 | 7,228 | 15,865,598 | Mar 30 |
| OEP VII GP, L.L.C. | 10% Owner | Mar 12 '26 | Buy | 9.73 | 689,336 | 6,707,170 | 15,864,871 | Mar 30 |
| OEP VII GP, L.L.C. | 10% Owner | Mar 11 '26 | Buy | 9.73 | 536,827 | 5,222,307 | 15,175,535 | Mar 30 |
| OEP VII GP, L.L.C. | 10% Owner | Mar 10 '26 | Buy | 9.73 | 820,528 | 7,982,671 | 14,638,708 | Mar 30 |
| CASHIN RICHARD M JR | 10% Owner | Mar 20 '26 | Buy | 9.91 | 447,100 | 4,431,700 | 16,312,698 | Mar 23 |
| CASHIN RICHARD M JR | 10% Owner | Mar 19 '26 | Buy | 9.94 | 727 | 7,228 | 15,865,598 | Mar 23 |
| Prast Albert A. | Chief Technology Officer | Mar 13 '26 | Option Exercise | 4.38 | 89,451 | 391,795 | 532,358 | Mar 16 |
| CASHIN RICHARD M JR | 10% Owner | Mar 12 '26 | Buy | 9.73 | 689,336 | 6,707,170 | 15,864,871 | Mar 12 |
| CASHIN RICHARD M JR | 10% Owner | Mar 11 '26 | Buy | 9.73 | 536,827 | 5,222,307 | 15,175,535 | Mar 12 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.